1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsAccelerates late-stage clinical development and pivotal trials for therapeutic and medical device technologies addressing pediatric and rare cancers. Requires prior qualifying NIH SBIR/STTR Phase II award and 1:1 matching funds.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: U. S. small businesses that have received a qualifying NIH SBIR or STTR Phase II award. Confirm the full requirements in the official notice before applying.
The current listing shows up to $15 million over 4 years. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was September 8, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
NCI SBIR Phase IIB Strategic Breakthrough Award is funded by National Cancer Institute (NCI). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Small Business Transition Grant for New Entrepreneurs (SBIR) — R43 Phase I is a grant from the National Institutes of Health (NIH) that funds early-stage scientific innovation by small businesses aiming to bring biomedical breakthroughs to the commercial marketplace. The Phase I award supports feasibility research, evaluating technical merit and commercial potential of proposed innovations. Eligible applicants are U.S. small business concerns, particularly new entrepreneurs, applying under PAR-24-131. Awards cover up to approximately $306,872 in total costs for Phase I. The most recent deadline is September 5, 2026.
NIH SBIR/STTR Parent SBIR (R43/R44) Clinical Trial Not Allowed (PA-24-245) is sponsored by National Institutes of Health (NIH). The NIH SBIR program supports small businesses developing innovative technologies that address health-related challenges through Phase I and Phase II funding, focusing on establishing technical feasibility, research and development, and advancing toward commercialization.
On May 21, 2026, the National Cancer Institute posted RFA-CA-27-006, RFA-CA-27-007, and RFA-CA-27-008 — the three competitive renewals for the NCI Community Oncology Research Program. Combined FY 2027 commitments reach $147.5 million across roughly 57 awards: $74.5 million for up to 7 Research Bases, $73 million for up to 50 Community and Academic Community Sites. Pre-application webinars run June 16-18 this week. Applications are due August 18, 2026 with six-year project periods. For community hospitals, oncology consortia, and NCI-designated cancer centers, this is the single largest cancer clinical-trials infrastructure decision NCI makes until 2033.
Read articleThe Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read article